PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.09%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
3.56%
G&A growth while TRAW reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
-26.91%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-26.91%
Both companies reducing total costs. Martin Whitman would check industry trends.
10.26%
Interest expense change of 10.26% while TRAW maintains costs. Bruce Berkowitz would investigate control.
-96.48%
D&A reduction while TRAW shows 11.22% growth. Joel Greenblatt would examine efficiency.
-115.63%
EBITDA decline while TRAW shows 16.28% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
27.06%
Operating income growth exceeding 1.5x TRAW's 16.10%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-198.08%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-304.05%
Pre-tax income decline while TRAW shows 15.38% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
113.79%
Tax expense change of 113.79% while TRAW maintains burden. Bruce Berkowitz would investigate strategy.
-304.05%
Net income decline while TRAW shows 15.38% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-302.06%
EPS decline while TRAW shows 35.79% growth. Joel Greenblatt would examine position.
-288.66%
Diluted EPS decline while TRAW shows 35.79% growth. Joel Greenblatt would examine position.
0.11%
Share count reduction exceeding 1.5x TRAW's 33.46%. David Dodd would verify capital allocation.
3.68%
Diluted share reduction exceeding 1.5x TRAW's 33.46%. David Dodd would verify capital allocation.